NCT03877003

Brief Summary

The objective of this study is to determine the effects of consuming either 3 eggs per day and compare it to daily choline supplement (choline bitartrate) for a dose of approximately 400 mg/day on plasma concentrations of high density lipoprotein cholesterol (HDL-c), trimethylamine N oxide (TMAO) and plasma choline. The goal is to determine if choline given as phosphatidyl choline (from eggs) will have a more beneficial effect on plasma choline and microbiota.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable coronary-artery-disease

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 13, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 15, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 14, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2020

Completed
Last Updated

November 3, 2020

Status Verified

November 1, 2020

Enrollment Period

1.1 years

First QC Date

March 13, 2019

Last Update Submit

November 2, 2020

Conditions

Keywords

eggs,cholinemetabolic syndromeTMAO

Outcome Measures

Primary Outcomes (2)

  • Plasma choline and TMAO (micromol/L)

    They will be measured simultaneously by use of a mass spectrophotometer

    1 year

  • Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL

    They will be measured simultaneoulsy by use of an automated spectrophotometer

    1 year

Secondary Outcomes (1)

  • Analysis of microbiota diversity (expressed as concentrations of different microorganisms.

    1 year

Study Arms (2)

Egg Intake

EXPERIMENTAL

Consumption of 3 eggs per day for breakfast during 4 weeks

Other: Eggs

Choline Supplement Intake

EXPERIMENTAL

Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks

Other: Eggs

Interventions

EggsOTHER

Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks

Also known as: Dietary supplement (choline bitartrate)
Choline Supplement IntakeEgg Intake

Eligibility Criteria

Age35 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All genders
  • years
  • Metabolic syndrome (based on 3 out of 5 characteristics: waist circumference \> 88 cm for women and \> 102 cm for men, plasma triglycerides \> 150 mg/dL, fasting glucose \> 100 mg/dL, blood pressure \> 135/85 and HDL \< 40 mg/dL for men and \< 50 mg/dL for women),
  • willing to consume 3 eggs per day for 4 weeks
  • willing to consume choline supplement (400 mg/day for 4 weeks)

You may not qualify if:

  • Self-reported diaberes, cardiovascular disease, history of stroke, liver disease or cancer
  • Taking glucose lowering medications
  • Taking antibiotics in the previous 1 month
  • Triglycerides \> 500 mg/dL,
  • Cholesterol \> 240 mg/dL,
  • blood pressure \> 145/100 mm of Hg
  • Allergic to eggs or to choline

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Nutritional Sciences

Storrs, Connecticut, 06269, United States

Location

University of Connecticut

Storrs, Connecticut, 06269, United States

Location

MeSH Terms

Conditions

Coronary Artery DiseaseDiabetes MellitusMetabolic Syndrome

Interventions

EggsDietary SupplementsCholine

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesInsulin ResistanceHyperinsulinism

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsOnium Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Randomized crossover design
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 13, 2019

First Posted

March 15, 2019

Study Start

November 1, 2018

Primary Completion

December 14, 2019

Study Completion

June 30, 2020

Last Updated

November 3, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations